INmune Bio Statistics
Total Valuation
INmune Bio has a market cap or net worth of $45.59 million. The enterprise value is $18.67 million.
Important Dates
The last earnings date was Thursday, October 30, 2025, after market close.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
INmune Bio has 26.59 million shares outstanding. The number of shares has increased by 25.31% in one year.
| Current Share Class | 26.59M |
| Shares Outstanding | 26.59M |
| Shares Change (YoY) | +25.31% |
| Shares Change (QoQ) | +14.11% |
| Owned by Insiders (%) | 17.01% |
| Owned by Institutions (%) | 17.95% |
| Float | 20.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 906.56 |
| Forward PS | n/a |
| PB Ratio | 1.73 |
| P/TBV Ratio | 1.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 373.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.17, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.17 |
| Quick Ratio | 4.10 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -942.22 |
Financial Efficiency
Return on equity (ROE) is -155.77% and return on invested capital (ROIC) is -64.04%.
| Return on Equity (ROE) | -155.77% |
| Return on Assets (ROA) | -50.59% |
| Return on Invested Capital (ROIC) | -64.04% |
| Return on Capital Employed (ROCE) | -134.08% |
| Revenue Per Employee | $2,273 |
| Profits Per Employee | -$2.27M |
| Employee Count | 22 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.63% in the last 52 weeks. The beta is 0.91, so INmune Bio's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | -65.63% |
| 50-Day Moving Average | 1.80 |
| 200-Day Moving Average | 4.72 |
| Relative Strength Index (RSI) | 50.82 |
| Average Volume (20 Days) | 382,642 |
Short Selling Information
The latest short interest is 3.45 million, so 12.98% of the outstanding shares have been sold short.
| Short Interest | 3.45M |
| Short Previous Month | 3.19M |
| Short % of Shares Out | 12.98% |
| Short % of Float | 16.74% |
| Short Ratio (days to cover) | 10.20 |
Income Statement
In the last 12 months, INmune Bio had revenue of $50,000 and -$49.89 million in losses. Loss per share was -$2.11.
| Revenue | 50,000 |
| Gross Profit | 50,000 |
| Operating Income | -34.86M |
| Pretax Income | -49.89M |
| Net Income | -49.89M |
| EBITDA | n/a |
| EBIT | -34.86M |
| Loss Per Share | -$2.11 |
Full Income StatementBalance Sheet
The company has $27.73 million in cash and $1.08 million in debt, giving a net cash position of $26.65 million or $1.00 per share.
| Cash & Cash Equivalents | 27.73M |
| Total Debt | 1.08M |
| Net Cash | 26.65M |
| Net Cash Per Share | $1.00 |
| Equity (Book Value) | 25.38M |
| Book Value Per Share | 0.95 |
| Working Capital | 23.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$30.65 million and capital expenditures -$899,000, giving a free cash flow of -$31.55 million.
| Operating Cash Flow | -30.65M |
| Capital Expenditures | -899,000 |
| Free Cash Flow | -31.55M |
| FCF Per Share | -$1.19 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -69,724.00% |
| Pretax Margin | -99,774.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
INmune Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.31% |
| Shareholder Yield | -25.31% |
| Earnings Yield | -110.06% |
| FCF Yield | -69.60% |
Analyst Forecast
The average price target for INmune Bio is $4.30, which is 150.73% higher than the current price. The consensus rating is "Hold".
| Price Target | $4.30 |
| Price Target Difference | 150.73% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 367.94% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
INmune Bio has an Altman Z-Score of -1.4 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.4 |
| Piotroski F-Score | 3 |
